News

Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms

January 06, 2021
• First joint CriVac® vaccine candidate to target receptor-binding domain of SARS-CoV-2 • Evaluation of Cristal's CliCr® and I...
Read more
Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms

Sapreme Appoints Björn Cochlovius as Chairman of its Board of Directors

December 17, 2020
Appointment of Björn Cochlovius, Ph.D. as Chairman of the Board
Read more
Sapreme Appoints Björn Cochlovius as Chairman of its Board of Directors

Sapreme Appoints Miriam Bujny as Chief Development Officer

October 27, 2020
Appointment of Miriam Bujny, Ph.D., as Chief Development Officer
Read more
Sapreme Appoints Miriam Bujny as Chief Development Officer

Positive DSMB Review in Phase 1/2a Study of ORCA-010in Treatment-Naïve Prostate Cancer Patients

October 15, 2020
Orca Therapeutics Announces Positive DSMB Review in Phase 1/2a Study of ORCA-010in Treatment-Naïve Prostate Cancer Patients
Read more
Positive DSMB Review in Phase 1/2a Study of ORCA-010in Treatment-Naïve Prostate Cancer Patients

Sapreme Unveils its Proprietary Endosomal Escape Platform in Presentations at 16th Annual Meeting of Oligonucleotide Therapeutics Society

September 30, 2020
positive preclinical data on its proprietary endosomal escape platform in two presentations at the 16th Annual Meeting of the O...
Read more
Sapreme Unveils its Proprietary Endosomal Escape Platform in Presentations at 16th Annual Meeting of Oligonucleotide Therapeutics Society

Cristal Therapeutics announces a publication in 'Chemical Science' on CliCr® technology platform

September 29, 2020
Cristal Therapeutics announces a publication in 'Chemical Science' on CliCr® technology platform, comprising a new class of sup...
Read more
Cristal Therapeutics announces a publication in 'Chemical Science' on CliCr® technology platform

Cristal Therapeutics Awarded Horizon 2020 Grant to Further Develop the CriPec® Nanomedicine Platform

July 02, 2020
Horizon 2020 INNOSUP grant allows the funding of a highly skilled and experienced researcher (Innovation Associate) to develop...
Read more
Cristal Therapeutics Awarded Horizon 2020 Grant to Further Develop the CriPec® Nanomedicine Platform

ISA Pharmaceuticals receives US Orphan-Drug Designation for ISA101b in HPV16-positive Cervical Cancer

July 01, 2020
Primes the immune system to attack cancer cells in HPV16-positive cancers
Read more
ISA Pharmaceuticals receives US Orphan-Drug Designation for ISA101b in HPV16-positive Cervical Cancer

ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration with Regeneron

June 17, 2020
ISA Pharmaceuticals and Regeneron
Read more

CATO SMS Signs Agreement with InteRNA to Facilitate Phase I Solid Tumor Trial

May 19, 2020
InteRNA and CATO SMS signed an agreement in which CATO SMS will conduct the Phase I clinical trial with microRNA mimic INT-1B3...
Read more
CATO SMS Signs Agreement with InteRNA to Facilitate Phase I Solid Tumor Trial

Cristal Therapeutics Publishes Positive Data on its CriPec® Nanomedicine Technology in Small

May 11, 2020
Small publication demonstrates that superior therapeutic profiles of CriPec® nanomedicines result from rational design
Read more
Cristal Therapeutics Publishes Positive Data on its CriPec® Nanomedicine Technology in Small

InteRNA Technologies Receives Regulatory Approval for Initiation of Phase I Clinical Trial of INT-1B3 in Patients with Advanced Solid Tumors

May 06, 2020
InteRNA Technologies Receives Regulatory Approval for Initiation of Phase I Clinical Trial of INT-1B3 in Patients with Advanced...
Read more
InteRNA Technologies Receives Regulatory Approval for Initiation of Phase I Clinical Trial of INT-1B3 in Patients with Advanced Solid Tumors

ISA Pharmaceuticals announces CervISA publication

March 19, 2020
Synergy between Synthetic Long Peptides (SLP®) immunotherapeutics and standard chemotherapy in late stage cancer including mean...
Read more
ISA Pharmaceuticals announces CervISA publication

MIMETAS to launch Assay Ready product line for Organ-on-a-Chip

March 03, 2020
MIMETAS announces the first product release of her Assay Ready product line: OrganoPlate® Caco-2. Innovative in-vitro models r...
Read more
MIMETAS to launch Assay Ready product line for Organ-on-a-Chip

Sapreme Technologies in a 6.8 M€ EU Alliance

February 20, 2020
Sapreme Technologies in a 6.8 M€ EU Alliance to Develop an Oligonucleotide Delivery Platform Based on Its Proprietary Endosomal...
Read more
Sapreme Technologies in a 6.8 M€ EU Alliance

Macrophage Pharma Expands Executive Team with Chief Scientific Officer and Chief Technology Officer

January 09, 2020
Key hires enhance management for next development phase
Read more
Macrophage Pharma Expands Executive Team with Chief Scientific Officer and Chief Technology Officer

Aglaia Oncology Funds and Sinzer - Grant Thornton Launch Dedicated Life Sciences Impact Measuring and Reporting Suite

December 19, 2019
• Enables visibility for investors of social impact realized by their investments • Suite demonstrates value beyond financial...
Read more
Aglaia Oncology Funds and Sinzer - Grant Thornton Launch Dedicated Life Sciences Impact Measuring and Reporting Suite

InteRNA presents data on drug formulation and mode of action of lead oncology development candidate INT-1B3 at the 15th annual OTS meeting

October 31, 2019
InteRNA presents data on drug formulation and mode of action of lead oncology development candidate INT-1B3 at the 15th annual...
Read more
InteRNA presents data on drug formulation and mode of action of lead oncology development candidate INT-1B3 at the 15th annual OTS meeting

Macrophage Pharma Appoints Dr Anker Lundemose to the Board of Directors

September 26, 2019
Macrophage Pharma Limited has appointed Dr. Anker Lundemose as independent non-executive director.
Read more
Macrophage Pharma Appoints Dr Anker Lundemose to the Board of Directors

Macrophage Pharma appoints Dr Søren Bregenholt as Chief Executive Officer

September 03, 2019
Macrophage Pharma Limited ('MPL') announced today that it has appointed Dr Søren Bregenholt as Chief Executive Officer....
Read more
Macrophage Pharma appoints Dr Søren Bregenholt as Chief Executive Officer

Home > News > Archive

© 2021 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds